Improvement in global functioning post‐treatment · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · children and adolescents with anxiety disorders
1 finding from 1 review
Reduction in anxiety symptoms (parent report) post‐treatment · children and adolescents with anxiety disorders
Reduction in depressive symptoms post‐treatment · children and adolescents with anxiety disorders
1 finding from 1 review
Improvement in global functioning post‐treatment · children and adolescents with anxiety disorders
1 finding from 1 review
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission of primary anxiety diagnosis post‐treatment (ITT) · children and adolescents with anxiety disorders
CBT showed no clear difference in remission of primary anxiety diagnosis post‐treatment (ITT) compared with treatment (low certainty).
1 finding from 1 review
Time to death from any cause · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT leads to lower time to death from any cause compared with ADT alone (high certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).
1 finding from 1 review
Time to death from prostate cancerMedian · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to lower time to death due to prostate cancer measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Time to progression · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to lower time to disease progression measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
treatment efficacyup to 6 months (5‐12 weeks) · depression in adults
Behavioural activation showed no clear difference in treatment efficacyup to 6 months (5‐16 weeks) compared with CBT (moderate certainty).
1 finding from 1 review
depression symptoms (continuous) up to 6 months (4‐8 weeks) · depression in adults
1 finding from 1 review
quality of life (continuous)up to 6 months (8 weeks) · depression in adults
1 finding from 1 review
Anxiety · depression in adults
1 finding from 1 review
Efficacy: number of participants who respond to treatment ‐ at 3 months · depression in adults
It is very uncertain whether behavioural activation changes treatment efficacy up to 6 months (12 weeks) compared with psychodynamic (very low certainty).
1 finding from 1 review
depression symptoms(continuous) up to 6 months (12 weeks) · depression in adults
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
Behavioural activation showed no clear difference in treatment acceptability up to 6 months (4‐16 weeks) compared with CBT (low certainty).
1 finding from 1 review